Aventis subsidiary Biochimica will pay Lilly $110 mil. for the settlement of all litigation regarding the antibiotic cefaclor. Lilly initiated a patent lawsuit in 1995 and a civil suit in 1997. Lilly's litigation against Ivax/Zenith is still ongoing
You may also be interested in...
The $33 mil. fine levied against Roussel Uclaf (now part of Aventis) for cefaclor manufacturing violations is based on the firm's operating profit from the sale of the generic antibiotic.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011